Pfizer, Avillion’s Bosulif comes out on top in first-line CML trial
Pfizer and partner Avillion have presented data from a late-stage study showing that Bosulif was better than Novartis’ Gleevec as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.
Read More
